Black Rock Inc. Corbus Pharmaceuticals Holdings, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.11 - $5.46 $471 - $23,401	-4,286 Reduced 0.18%	2,355,555 $259,000
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $1,234 - $38,545	-7,259 Reduced 0.31%	2,359,841 $389,000
Q2 2022 Aug 12, 2022	SELL	$0.21 - $0.53 $39,789 - $100,420	-189,473 Reduced 7.41%	2,367,100 $596,000
Q1 2022 May 12, 2022	BUY	$0.32 - $0.67 $3,014 - $6,311	9,420 Added 0.37%	2,556,573 $1.36 Million
Q4 2021 Feb 10, 2022	SELL	$0.6 - $1.11 $11,574 - $21,411	-19,290 Reduced 0.75%	2,547,153 $1.57 Million
Q3 2021 Nov 09, 2021	BUY	$1.01 - $1.82 $206,415 - $371,957	204,372 Added 8.65%	2,566,443 $2.62 Million
Q2 2021 Aug 11, 2021	BUY	$1.39 - $2.21 $3.28 Million - $5.22 Million	2,362,071 New	2,362,071 $4.32 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.